結核病藥物市場：依疾病（活動性結核病、潛伏性結核病）、藥物類別（組合藥物、第一線抗結核藥物、第二線抗結核藥物）－2023-2030年全球預測

預計2023年全球抗結核藥物市場將達到192972萬美元，年複合成長率為6.26%，預計到2030年將出現驚人成長，達到295593萬美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球結核病藥物市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對總收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球結核病藥物市場規模及預測為何？

2.在預測期內，COVID-19 對全球結核病治療藥物市場的阻礙因素和影響為何？

3.在預測期內，全球結核病藥物市場需要投資哪些產品/細分市場/應用/領域？

4.全球結核病藥物市場的競爭策略是什麼？

5. 全球結核病藥物市場的技術趨勢和法律規範是什麼？

6.全球結核病藥物市場主要廠商的市佔率是多少？

7. 哪些型態和策略性措施被認為適合進入全球結核病藥物市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

• 市場動態
  • 促進因素
    • 全球抗藥結核病計畫將促進診斷和治療登記
    • HIV 感染導致 LTBI 病例增加
    • 結核病罹患率上升
  • 抑制因素
    • 耐多藥和廣泛抗藥性結核病藥物高成本
  • 機會
    • 加大開發新藥研發力度
    • 政府機構擴大結核病宣傳活動
  • 任務
    • 結核病藥物的副作用
• 市場趨勢
• COVID-19 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通膨的累積效應
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 法律規範
• 客戶客製化

第6章 結核病治療藥物市場：依疾病分類

• 活動性結核病
• 潛伏性結核病

第7章 依藥物類別分類的結核病藥物市場

• 組合藥物
• 一線抗結核藥物
  • 依三丁醇
  • 異煙肼
  • 吡嗪醯胺
  • 利福平
• 二線抗結核藥
  • 捲曲黴素
  • 乙硫異煙胺
  • 左氧氟沙星
  • 鏈黴素

第8章 美洲結核病藥物市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第9章 亞太結核病藥物市場

• 澳洲
• 中國
• 印度
• 印尼
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第10章 歐洲、中東和非洲結核病藥物市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 義大利
• 荷蘭
• 奈及利亞
• 挪威
• 波蘭
• 卡達
• 俄羅斯
• 沙烏地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公國
• 英國

第11章競爭形勢

• FPNV定位矩陣
• 市佔率分析：主要企業
• 競爭情境分析：主要企業

第12章上市公司名單

第13章附錄

• 討論指南
• 關於許可證和定價

The Global Tuberculosis Drugs Market is forecasted to grow significantly, with a projected USD 1,929.72 million in 2023 at a CAGR of 6.26% and expected to reach a staggering USD 2,955.93 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Tuberculosis Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Tuberculosis Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Disease, market is studied across Active TB and Latent TB. The Active TB is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Combination Drugs, First-line Anti-TB Drugs, and Second-line Anti-TB Drugs. The First-line Anti-TB Drugs is further studied across Ethambutol, Isoniazid, Pyrazinamide, and Rifampin. The Second-line Anti-TB Drugs is further studied across Capreomycin, Ethionamide, Levofloxacin, and Streptomycin. The Combination Drugs is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Tuberculosis Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Tuberculosis Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Tuberculosis Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Tuberculosis Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Tuberculosis Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Tuberculosis Drugs Market?

6. What is the market share of the leading vendors in the Global Tuberculosis Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Tuberculosis Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Tuberculosis Drugs Market, by Disease, 2022 vs 2030
• 4.3. Tuberculosis Drugs Market, by Drug Class, 2022 vs 2030
• 4.4. Tuberculosis Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Global plan against drug-resistant TB drives diagnosis and treatment enrollment
    • 5.1.1.2. HIV burden fuels LTBI case counts
    • 5.1.1.3. Rising prevalence of tuberculosis
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of MDR and XDR TB drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing research & development of new drug development
    • 5.1.3.2. Growing initiative from government organization for tuberculosis awareness
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse side effects of tuberculosis drugs
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Tuberculosis Drugs Market, by Disease

• 6.1. Introduction
• 6.2. Active TB
• 6.3. Latent TB

7. Tuberculosis Drugs Market, by Drug Class

• 7.1. Introduction
• 7.2. Combination Drugs
• 7.3. First-line Anti-TB Drugs
  • 7.3.1. Ethambutol
  • 7.3.2. Isoniazid
  • 7.3.3. Pyrazinamide
  • 7.3.4. Rifampin
• 7.4. Second-line Anti-TB Drugs
  • 7.4.1. Capreomycin
  • 7.4.2. Ethionamide
  • 7.4.3. Levofloxacin
  • 7.4.4. Streptomycin

8. Americas Tuberculosis Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Tuberculosis Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Tuberculosis Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. TUBERCULOSIS DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. TUBERCULOSIS DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. TUBERCULOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2022 VS 2030 (%)
• FIGURE 5. TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 6. TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. TUBERCULOSIS DRUGS MARKET DYNAMICS
• FIGURE 8. TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. TUBERCULOSIS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. TUBERCULOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 5. TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. TUBERCULOSIS DRUGS MARKET SIZE, BY LATENT TB, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 10. TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. TUBERCULOSIS DRUGS MARKET SIZE, BY ETHAMBUTOL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. TUBERCULOSIS DRUGS MARKET SIZE, BY ISONIAZID, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. TUBERCULOSIS DRUGS MARKET SIZE, BY PYRAZINAMIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. TUBERCULOSIS DRUGS MARKET SIZE, BY RIFAMPIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 16. TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. TUBERCULOSIS DRUGS MARKET SIZE, BY CAPREOMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. TUBERCULOSIS DRUGS MARKET SIZE, BY ETHIONAMIDE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. TUBERCULOSIS DRUGS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. TUBERCULOSIS DRUGS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 34. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 37. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 56. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 57. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 59. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 60. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 61. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 63. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 129. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 130. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 131. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 132. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 145. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 146. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 147. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 148. POLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 149. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 150. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 151. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 152. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
• TABLE 189. TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 190. TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 191. TUBERCULOSIS DRUGS MARKET LICENSE & PRICING